Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 31Gastrointestinal 31Genitourinary 3Thoracic 2Head & Neck 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 10Small Cell Lung Carcinoma 6Thymoma 5Carcinoma, Renal Cell 4Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Gastrointestinal Stromal Tumors 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thoracic Neoplasms 1Somatostatinoma 1Recurrence 1Rectal Neoplasms 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nervous System Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma 1

Interventions

Sunitinib 2Erlotinib Hydrochloride 2trastuzumab deruxtecan 1tinostamustine 1spartalizumab 1ripretinib 1ribociclib 1pexidartinib 1pembrolizumab 1motexafin lutetium 1Thalidomide 1Psychiatric Rehabilitation 1OSI 930 1Midazolam 1Irinotecan 1Injections 1Fentanyl 1Early Intervention, Educational 1Drug Therapy 1Docetaxel 1Counseling 1Cisplatin 1Cetuximab 1Capecitabine 1Caffeine 17-hydroxystaurosporine 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × Sunitinib × Thoracic × Clear all
NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡